Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Borderi

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
The New Microbiologica|January 22, 2024
Optimizing the antiretroviral treatment focusing on long-term effectiveness and a person-centered approach. Consensus Guidance Using a Delphi ProcessFranco Maggiolo, Sergio Lo Caputo, Stefano Bonora, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 10, 2011
Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohortFabio Vescini, Alessandro Cozzi-Lepri, Marco Borderi, et al.
The New Microbiologica|July 7, 2015
Calcaneal quantitative ultrasound (QUS) and dual X-ray absorptiometry (DXA) bone analysis in adult HIV-positive patientsAlberto Clò, Davide Gibellini, Davide Damiano, et al.
HIV Clinical Trials|April 3, 2003
Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAARTGiovanni Guaraldi, Rita Murri, Gabriella Orlando, et al.
Retrovirology|May 27, 2011
HIV-1 and recombinant gp120 affect the survival and differentiation of human vessel wall-derived mesenchymal stem cellsDavide Gibellini, Francesco Alviano, Anna Miserocchi, et al.
The Journal of Antimicrobial Chemotherapy|March 7, 2016
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trialLaura Galli, Vincenzo Spagnuolo, Alba Bigoloni, et al.
AIDS Patient Care and Stds|February 19, 2015
Prevalence and predictors of low bone mineral density and fragility fractures among HIV-infected patients at one Italian center after universal DXA screening: sensitivity and specificity of current guidelines on bone mineral density managementElena Mazzotta, Tamara Ursini, Adriana Agostinone, et al.
The New Microbiologica|November 2, 2013
Phalangeal quantitative ultrasound: cheaper methods for screening and follow-up of bone pathologies in HIV-infected women?Roberta Prinapori, Rffaella Rosso, Antonio Di Biagio, et al.
BMC Infectious Diseases|February 16, 2012
Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenzEmanuele Focà, Davide Motta, Marco Borderi, et al.
Expert Review of Anti-Infective Therapy|October 15, 2020
Enhancing care for people living with HIV: current and future monitoring approachesFranco Maggiolo, Alessandra Bandera, Stefano Bonora, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
The New Microbiologica|January 22, 2024
Optimizing the antiretroviral treatment focusing on long-term effectiveness and a person-centered approach. Consensus Guidance Using a Delphi ProcessFranco Maggiolo, Sergio Lo Caputo, Stefano Bonora, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 10, 2011
Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohortFabio Vescini, Alessandro Cozzi-Lepri, Marco Borderi, et al.
The New Microbiologica|July 7, 2015
Calcaneal quantitative ultrasound (QUS) and dual X-ray absorptiometry (DXA) bone analysis in adult HIV-positive patientsAlberto Clò, Davide Gibellini, Davide Damiano, et al.
HIV Clinical Trials|April 3, 2003
Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAARTGiovanni Guaraldi, Rita Murri, Gabriella Orlando, et al.
Retrovirology|May 27, 2011
HIV-1 and recombinant gp120 affect the survival and differentiation of human vessel wall-derived mesenchymal stem cellsDavide Gibellini, Francesco Alviano, Anna Miserocchi, et al.
The Journal of Antimicrobial Chemotherapy|March 7, 2016
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trialLaura Galli, Vincenzo Spagnuolo, Alba Bigoloni, et al.
AIDS Patient Care and Stds|February 19, 2015
Prevalence and predictors of low bone mineral density and fragility fractures among HIV-infected patients at one Italian center after universal DXA screening: sensitivity and specificity of current guidelines on bone mineral density managementElena Mazzotta, Tamara Ursini, Adriana Agostinone, et al.
The New Microbiologica|November 2, 2013
Phalangeal quantitative ultrasound: cheaper methods for screening and follow-up of bone pathologies in HIV-infected women?Roberta Prinapori, Rffaella Rosso, Antonio Di Biagio, et al.
BMC Infectious Diseases|February 16, 2012
Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenzEmanuele Focà, Davide Motta, Marco Borderi, et al.
Expert Review of Anti-Infective Therapy|October 15, 2020
Enhancing care for people living with HIV: current and future monitoring approachesFranco Maggiolo, Alessandra Bandera, Stefano Bonora, et al.
Pageof 7